Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways

Amyotrophic Lateral Sclerosis (ALS) is a progressive and disabling neurodegenerative disorder characterized by upper and lower motor neuron loss, leading to respiratory insufficiency and death after 3-5 years. Riluzole is currently the only FDA approved drug for ALS, but it has only modest effects o...

Descripción completa

Detalles Bibliográficos
Autores principales: Paratore, Sabrina, Pezzino, Salvatore, Cavallaro, Sebastiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394120/
https://www.ncbi.nlm.nih.gov/pubmed/23204922
http://dx.doi.org/10.2174/138920212800793366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394120/
https://www.ncbi.nlm.nih.gov/pubmed/23204922
http://dx.doi.org/10.2174/138920212800793366

Ejemplares similares